Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

405 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.
Fisher MD, Watson C, Fox KM, Chen YW, Gandra SR. Fisher MD, et al. Among authors: fox km. Curr Med Res Opin. 2013 May;29(5):561-8. doi: 10.1185/03007995.2013.786693. Epub 2013 Apr 3. Curr Med Res Opin. 2013. PMID: 23489410
Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
Bonafede MM, Fox KM, Johnson BH, Watson C, Gandra SR. Bonafede MM, et al. Among authors: fox km. Clin Ther. 2012 Feb;34(2):457-67. doi: 10.1016/j.clinthera.2011.12.016. Epub 2012 Jan 28. Clin Ther. 2012. PMID: 22284901
Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM, Gandra SR, Fox KM, Wilson KL. Bonafede MM, et al. Among authors: fox km. J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1. J Med Econ. 2012. PMID: 22332705
Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
Yeaw J, Watson C, Fox KM, Schabert VF, Goodman S, Gandra SR. Yeaw J, et al. Among authors: fox km. Adv Ther. 2014 Apr;31(4):410-25. doi: 10.1007/s12325-014-0110-3. Epub 2014 Mar 7. Adv Ther. 2014. PMID: 24604700
National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT, Gandra SR, Fox KM, Smith TW, Pill MW. Joyce AT, et al. Among authors: fox km. J Med Econ. 2014 Jan;17(1):1-10. doi: 10.3111/13696998.2013.856314. Epub 2013 Oct 31. J Med Econ. 2014. PMID: 24131136
Tumor necrosis factor-blocker dose escalation in rheumatoid arthritis patients in a pharmacy benefit management setting.
Blume SW, Fox KM, Joseph G, Chuang CC, Thomas J, Gandra SR. Blume SW, et al. Among authors: fox km. Adv Ther. 2013 May;30(5):517-27. doi: 10.1007/s12325-013-0034-3. Epub 2013 Jun 6. Adv Ther. 2013. PMID: 23740359 Free PMC article.
Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting.
Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Bonafede M, et al. Among authors: fox km. J Dermatolog Treat. 2013 Oct;24(5):369-73. doi: 10.3109/09546634.2012.755255. Epub 2013 May 21. J Dermatolog Treat. 2013. PMID: 23441722 Free PMC article.
Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B, Fox KM, Watson C, Gandra SR. Chastek B, et al. Among authors: fox km. Adv Ther. 2012 Aug;29(8):691-7. doi: 10.1007/s12325-012-0039-3. Epub 2012 Aug 16. Adv Ther. 2012. PMID: 22903239
Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Bonafede M, et al. Among authors: fox km. Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8. Adv Ther. 2012. PMID: 22886712
Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population.
Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Chastek B, et al. Among authors: fox km. J Dermatolog Treat. 2013 Feb;24(1):25-33. doi: 10.3109/09546634.2012.661038. Epub 2012 Jun 5. J Dermatolog Treat. 2013. PMID: 22668321
405 results
Jump to page
Feedback